Lemelson–MIT Prize

Eight High School Teams Named Lemelson-MIT InvenTeams® Kicking Off the 20th Anniversary of the Grants Initiative

Retrieved on: 
Tuesday, October 24, 2023

The InvenTeams were selected by a respected panel consisting of university professors, inventors, entrepreneurs, industry professionals, and college students.

Key Points: 
  • The InvenTeams were selected by a respected panel consisting of university professors, inventors, entrepreneurs, industry professionals, and college students.
  • This year’s teams are:
    e3 Civic High (San Diego, Calif.)
    Cold Spring Harbor Junior/Senior High School (Cold Spring Harbor, N.Y.)
    Calistoga Junior/Senior High School (Calistoga, Calif.)
    Incline High School (Incline Village, Nev.)
    Cincinnati Country Day School (Cincinnati, Ohio)
    Chattahoochee High School (Johns Creek, Ga.)
    Amherst Regional High School (Amherst, Mass.)
  • “Teams are focusing their technological solutions – their inventions – on inequities in health and wellbeing, environmental issues, and safety concerns.
  • These high school students are not just problem-solvers of tomorrow, they are problem solvers today helping to make our world more equitable, healthier, and safer.”
    The InvenTeams initiative, now in its 20th year, has enabled 17 teams of high school students to earn U.S. patents for their projects.

MED-EL Presents: ideas4ears and calls for child inventors to aim high for people living with hearing loss

Retrieved on: 
Thursday, November 17, 2022

INNSBRUCK, Austria, Nov. 17, 2022 /PRNewswire/ -- MED-EL, a leading provider and inventor of hearing implant systems, today launched its annual worldwide search for inventions of the future through a global children's contest, ideas4ears.               

Key Points: 
  • The contest invites children aged 6-12 years old from around the world to create an invention to improve the quality of life for people with hearing loss.
  • The inspiration behind ideas4ears and the Head Judge of the contest is Geoffrey Ball.
  • Geoffrey has an extraordinary life story, when he became deaf as a toddler, he then went on to invent a revolutionary middle ear implant to treat his own hearing loss.
  • The ideas4ears contest celebrates children's creativity and aims to improve understanding of the challenges associated with hearing loss as well as the benefits of treatment.

Students at Tampa's Cambridge Christian School Win Grant from Lemelson-MIT for Invention to Help Thwart Devastation of Red Tide in Florida

Retrieved on: 
Monday, November 15, 2021

"The winning invention concept was created by the 12 students in the class," said Mary Saville, one of two Cambridge Christian School educators who act as coaches for the students.

Key Points: 
  • "The winning invention concept was created by the 12 students in the class," said Mary Saville, one of two Cambridge Christian School educators who act as coaches for the students.
  • "The students are also responsible for the rigorous grant application, financial reporting, technical design, assembly, testing, coding, and more."
  • Founded in 1964, Cambridge Christian School is a college preparatory school serving students 3 months to 12th grade from a Christ-centered worldview.
  • The school is nationally accredited by the National Council for Private School Accreditation, Christian Schools of Florida, and AdvancEd.

Valo Health Welcomes Leading Life Sciences and Technology Expert Judy Lewent to Board of Directors

Retrieved on: 
Thursday, June 24, 2021

We are thrilled to bring aboard such a well-respected leader," said David Berry, CEO of Valo Health.

Key Points: 
  • We are thrilled to bring aboard such a well-respected leader," said David Berry, CEO of Valo Health.
  • In addition, she is a life member of the MIT Corporation and a member of the American Academy of Arts & Sciences.
  • Valo Health, LLC ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence ("AI") driven computation.
  • Neither Valo nor KVAC gives any assurance that either Valo or KVAC, or the combined company, will achieve its expectations.

Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Monday, May 10, 2021

Stock-based compensation expense increased to $0.8 million from $0.2 million for the three months ended March 31, 2021 and 2020, respectively.

Key Points: 
  • Stock-based compensation expense increased to $0.8 million from $0.2 million for the three months ended March 31, 2021 and 2020, respectively.
  • The increase in general and administrative expenses was primarily driven by $1.0 million in increased costs from operating as a public company in the first quarter of 2021.
  • The engineered cells are protected by Sigilon\xe2\x80\x99s Afibromer\xe2\x84\xa2 biomaterials matrix, which shields them from immune rejection and fibrosis.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.\nThis press release includes forward-looking statements.

Valo Health to Participate in Financial Times US Pharma and Biotech Summit

Retrieved on: 
Thursday, April 29, 2021

b'BOSTON, April 29, 2021 /PRNewswire/ -- Valo Health, LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will participate in a panel discussion during the Financial Times US Pharma and Biotech Summit on Wednesday, May 5, 2021 at 11:30 AM ET.\nThe panel, " Navigating the pharma investment landscape ," will focus on emerging investment trends in the areas of therapeutics, technology, and M&A.\nValo Health, LLC (Valo) is a technology company that is using human-centric data and artificial intelligence (AI) computation to transform the drug discovery and development process.

Key Points: 
  • b'BOSTON, April 29, 2021 /PRNewswire/ -- Valo Health, LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will participate in a panel discussion during the Financial Times US Pharma and Biotech Summit on Wednesday, May 5, 2021 at 11:30 AM ET.\nThe panel, " Navigating the pharma investment landscape ," will focus on emerging investment trends in the areas of therapeutics, technology, and M&A.\nValo Health, LLC (Valo) is a technology company that is using human-centric data and artificial intelligence (AI) computation to transform the drug discovery and development process.
  • As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.
  • The company\'s Opal Computational Platform, a fully integrated, computational, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.
  • Founded by Flagship Pioneering and headquartered in Boston, MA, Valo has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/valo-health-to-participate-in-fi...\n'

Valo Health to Present at the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

Retrieved on: 
Tuesday, April 6, 2021

BOSTON, April 6, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will present at the BMO BioPharma Spotlight Series on Friday, April 16, 2021, at 11:55 ET.

Key Points: 
  • BOSTON, April 6, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will present at the BMO BioPharma Spotlight Series on Friday, April 16, 2021, at 11:55 ET.
  • Berry's presentation will be part of BMO's series entitled "Company Spotlights: Technology-Enabled Drug Discovery."
  • During the presentation, Berry will provide an overview of Valo, its Opal Computational Platform and a selection of its therapeutic programs.
  • Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process.

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 18, 2021

Net Loss: Net loss was $15.2 million for the quarter ended December 31, 2020 compared to $14.7 million for the same period of 2019.

Key Points: 
  • Net Loss: Net loss was $15.2 million for the quarter ended December 31, 2020 compared to $14.7 million for the same period of 2019.
  • For the full year 2020, Sigilon reported a net loss of $54.6million, compared to a net loss of $43.9 million for the full year 2019.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Valo Announces Technology & Product Management Expert Nish Lathia as Chief Product Officer

Retrieved on: 
Monday, March 1, 2021

As a leading expert in product, engineering, program management, and user experience, Nish will be a crucial member of the Valo leadership team, reporting to David Berry, Ph.D., Valo founder, and CEO.

Key Points: 
  • As a leading expert in product, engineering, program management, and user experience, Nish will be a crucial member of the Valo leadership team, reporting to David Berry, Ph.D., Valo founder, and CEO.
  • "I am thrilled that Nish has joined the executive team at Valo," said David Berry.
  • "Our work will build a powerful engineering and product team on the foundation that Valo has developed over the last two years," Lathia said.
  • Lathia's obsessive customer focus, deep curiosity, and wealth of product, technology, and operations knowledge will be an extraordinary addition to Valo.

Valo Health to Participate in Barclays and Oppenheimer Healthcare Investor Conferences

Retrieved on: 
Monday, March 1, 2021

BOSTON, March 1, 2021 /PRNewswire/ -- Valo Health, LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, announced today that its CEO and founder, David Berry, will present at the following investor conferences in March:

Key Points: 
  • BOSTON, March 1, 2021 /PRNewswire/ -- Valo Health, LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, announced today that its CEO and founder, David Berry, will present at the following investor conferences in March:
    A replay of the Barclays webcast will be available on the Valo LinkedIn page and the Valo website after the event.
  • Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process.
  • The company's Opal Computational Platform, a fully integrated, computational, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.
  • Founded by Flagship Pioneering and headquartered in Boston, MA, Valo has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com .